Trials / Recruiting
RecruitingNCT05287464
International Multicentric Study ARON-1
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,220 (estimated)
- Sponsor
- Hospital of Macerata · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pembrolizumab plus axitinib | collect global experiences with the use of immuno-combinations in patients with metastatic RCC |
Timeline
- Start date
- 2022-03-10
- Primary completion
- 2024-06-01
- Completion
- 2027-09-30
- First posted
- 2022-03-18
- Last updated
- 2025-11-26
Locations
1 site across 1 country: Italy
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05287464. Inclusion in this directory is not an endorsement.